Accolade Inc (ACCD)

$7.02 -0.01 (-0.14%)
Market Cap 575.59M
Revenue (ttm) 414.29M
Net Income (ttm) -99.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -24.09%
Debt to Equity Ratio 0.67
Volume 4,585,600
Avg Vol 1,421,620
Day's Range N/A - N/A
Shares Out 81.99M
Stochastic %K 80%
Beta 2.10
Analysts Sell
Price Target $6.54

Company Profile

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists,...

Industry: Health Information Services
Sector: Healthcare
Phone: 206 926 8100
Address:
1201 Third Avenue, Suite 1700, Seattle, United States
phillysea12
phillysea12 Apr. 8 at 2:06 PM
$ACCD piece of shit stock. 😡
0 · Reply
G101SPM
G101SPM Apr. 8 at 1:30 PM
$ACCD $7.02 bid. *DAC (7) $4.62. EXIT $12.00. BRIEF: Accolade: Transcarent announced the successful completion of its merger with Accolade. note: The transaction, valued at approximately $621 million, has received all necessary regulatory and shareholder approvals and Accolade is now part of a privately held company, and its common stock will no longer be listed on Nasdaq. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
1 · Reply
Mergerbrief
Mergerbrief Apr. 7 at 12:15 PM
$ACCD / Transcarent - Possible Close
0 · Reply
G101SPM
G101SPM Apr. 4 at 2:19 PM
$ACCD $7.02 bid. * DAC (dollar average cost includes 7 transactions to reduce cost to $4.62). Last at $3.60 (6.28.24). CHANGE EXIT TO $12.00 FROM $8.50. UPDATE: The merger is tentatively scheduled to close prior to the market open on April 8, 2025, subject to regulatory approval. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on April 7, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (April 8th) and will be suspended effective April 9, 2025. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 30 at 4:29 AM
$ACCD Digging ACCD's personalized healthcare play. Innovative data-driven approach targeting complex healthcare navigation. Watching how they scale and expand their member base. Potential long-term healthcare tech winner. great article: https://beyondspx.com/article/accolade-accd-delivering-personalized-healthcare-solutions-at-scale
0 · Reply
Mergerbrief
Mergerbrief Mar. 27 at 12:23 PM
$ACCD / Transcarent - $ACCD Shareholder Vote
0 · Reply
EZ_Money11
EZ_Money11 Feb. 28 at 12:20 PM
$ACCD Maybe wait to see if it fills the gap around $3.70…..
0 · Reply
ribockski
ribockski Feb. 24 at 3:37 AM
1. Accolade Inc. ($ACCD): A healthcare company, Accolade has experienced a significant 97% increase in its stock price over the past 30 days, indicating strong growth potential. 2. Akero Therapeutics Inc. ($AKRO): A biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH), Akero has seen its stock price rise by 96.2% over the past month. 3. OppFi Inc. ($OPFI): A financial technology company, OppFi has demonstrated a 93.1% increase in its stock price over the past 30 days, suggesting robust growth prospects.
0 · Reply
Quantum_Capital_LLC
Quantum_Capital_LLC Feb. 23 at 10:57 AM
$MPLN $APPS $CRNC $TUYA what I am currently buying/accumulating; they have strong momentum & technical indicators are favorable for either near term bullish move or long term positive move. $ACCD on watch.
0 · Reply
ajmrtxl
ajmrtxl Feb. 18 at 4:15 PM
$ACCD latest data from Squeezefinder
0 · Reply
Latest News on ACCD
TalkingParents Takes Home 11th Accolade For Support Network Initiative

Aug 12, 2025, 10:00 AM EDT - 2 months ago

TalkingParents Takes Home 11th Accolade For Support Network Initiative

The One Show Announces Historic Win: Klick Health Becomes First Health Agency to Ever Receive An Agency of the Year Accolade

May 16, 2025, 9:51 AM EDT - 5 months ago

The One Show Announces Historic Win: Klick Health Becomes First Health Agency to Ever Receive An Agency of the Year Accolade

Wellspring Launches Next-Gen Innovation Platform, Accolade Core

May 8, 2025, 9:00 AM EDT - 6 months ago

Wellspring Launches Next-Gen Innovation Platform, Accolade Core

Pernod completes sale of wine portfolio to Accolade Wines owner

Apr 30, 2025, 2:45 AM EDT - 6 months ago

Pernod completes sale of wine portfolio to Accolade Wines owner

Digital health startup Transcarent takes Accolade private in $621 million deal

Apr 8, 2025, 9:55 AM EDT - 7 months ago

Digital health startup Transcarent takes Accolade private in $621 million deal

Transcarent Completes Merger With Accolade

Apr 8, 2025, 9:22 AM EDT - 7 months ago

Transcarent Completes Merger With Accolade

Accolade Stockholders Approve Merger Between Accolade and Transcarent

Mar 27, 2025, 4:05 PM EDT - 7 months ago

Accolade Stockholders Approve Merger Between Accolade and Transcarent

Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

Mar 6, 2025, 9:00 AM EST - 8 months ago

Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

Feb 24, 2025, 5:20 PM EST - 8 months ago

Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

Accolade Expands Virtual Care to Medicare Beneficiaries Nationwide Through PlushCare Direct-to-Consumer Offering

Feb 4, 2025, 9:00 AM EST - 9 months ago

Accolade Expands Virtual Care to Medicare Beneficiaries Nationwide Through PlushCare Direct-to-Consumer Offering

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Accolade

Jan 10, 2025, 8:24 PM EST - 10 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Accolade

ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc. - ACCD

Jan 8, 2025, 5:48 PM EST - 10 months ago

ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc. - ACCD

Why Is Accolade Stock Trading Over 100% On Tuesday?

Jan 8, 2025, 1:33 PM EST - 10 months ago

Why Is Accolade Stock Trading Over 100% On Tuesday?

Healthcare M&A: Transcarent paying $621M to acquire Seattle-based health benefits firm Accolade

Jan 8, 2025, 11:07 AM EST - 10 months ago

Healthcare M&A: Transcarent paying $621M to acquire Seattle-based health benefits firm Accolade

Transcarent To Acquire Accolade

Jan 8, 2025, 8:30 AM EST - 10 months ago

Transcarent To Acquire Accolade

Accolade to Announce Fiscal Third Quarter 2025 Financial Results

Dec 16, 2024, 8:00 AM EST - 11 months ago

Accolade to Announce Fiscal Third Quarter 2025 Financial Results

Accolade: A GARP Stock Trading Well Under 1X Revenues

Dec 5, 2024, 5:05 AM EST - 11 months ago

Accolade: A GARP Stock Trading Well Under 1X Revenues

Accolade To Present at Upcoming Investor Conferences

Nov 13, 2024, 8:00 AM EST - 1 year ago

Accolade To Present at Upcoming Investor Conferences

Porter Airlines Receives Another Accolade with APEX Four Star Major Airline Rating

Oct 31, 2024, 9:03 AM EDT - 1 year ago

Porter Airlines Receives Another Accolade with APEX Four Star Major Airline Rating

Accolade Welcomes Renalogic to Trusted Partner Ecosystem

Oct 15, 2024, 9:00 AM EDT - 1 year ago

Accolade Welcomes Renalogic to Trusted Partner Ecosystem

Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript

Oct 8, 2024, 10:27 AM EDT - 1 year ago

Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript

Accolade Inc (ACCD) Q2 Earnings: Revenue Hits $106.4M, Beating Estimates; GAAP EPS Loss at $0.30

Oct 8, 2024, 8:31 AM EDT - 1 year ago

Accolade Inc (ACCD) Q2 Earnings: Revenue Hits $106.4M, Beating Estimates; GAAP EPS Loss at $0.30

Accolade Announces Results for Fiscal Second Quarter 2025

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Accolade Announces Results for Fiscal Second Quarter 2025

Accolade Inc (ACCD) Q2 2025: Everything You Need to Know Ahead of Earnings

Oct 7, 2024, 8:01 AM EDT - 1 year ago

Accolade Inc (ACCD) Q2 2025: Everything You Need to Know Ahead of Earnings

Top Wall Street Forecasters Revamp Accolade Price Expectations Ahead Of Q2 Earnings

Oct 4, 2024, 4:19 AM EDT - 1 year ago

Top Wall Street Forecasters Revamp Accolade Price Expectations Ahead Of Q2 Earnings

Accolade to Announce Fiscal Second Quarter 2025 Financial Results

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Accolade to Announce Fiscal Second Quarter 2025 Financial Results

Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference

First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies

Aug 22, 2024, 10:03 AM EDT - 1 year ago

First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies

Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

The Schall Law Firm Encourages Accolade Inc Investors To Join The Alleged Securities Fraud Probe

Jul 30, 2024, 9:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Accolade Inc Investors To Join The Alleged Securities Fraud Probe

The Schall Law Firm Urges Accolade Inc Investors To Participate In The Alleged Securities Fraud Probe

Jul 29, 2024, 3:45 PM EDT - 1 year ago

The Schall Law Firm Urges Accolade Inc Investors To Participate In The Alleged Securities Fraud Probe

phillysea12
phillysea12 Apr. 8 at 2:06 PM
$ACCD piece of shit stock. 😡
0 · Reply
G101SPM
G101SPM Apr. 8 at 1:30 PM
$ACCD $7.02 bid. *DAC (7) $4.62. EXIT $12.00. BRIEF: Accolade: Transcarent announced the successful completion of its merger with Accolade. note: The transaction, valued at approximately $621 million, has received all necessary regulatory and shareholder approvals and Accolade is now part of a privately held company, and its common stock will no longer be listed on Nasdaq. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
1 · Reply
Mergerbrief
Mergerbrief Apr. 7 at 12:15 PM
$ACCD / Transcarent - Possible Close
0 · Reply
G101SPM
G101SPM Apr. 4 at 2:19 PM
$ACCD $7.02 bid. * DAC (dollar average cost includes 7 transactions to reduce cost to $4.62). Last at $3.60 (6.28.24). CHANGE EXIT TO $12.00 FROM $8.50. UPDATE: The merger is tentatively scheduled to close prior to the market open on April 8, 2025, subject to regulatory approval. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on April 7, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (April 8th) and will be suspended effective April 9, 2025. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 30 at 4:29 AM
$ACCD Digging ACCD's personalized healthcare play. Innovative data-driven approach targeting complex healthcare navigation. Watching how they scale and expand their member base. Potential long-term healthcare tech winner. great article: https://beyondspx.com/article/accolade-accd-delivering-personalized-healthcare-solutions-at-scale
0 · Reply
Mergerbrief
Mergerbrief Mar. 27 at 12:23 PM
$ACCD / Transcarent - $ACCD Shareholder Vote
0 · Reply
EZ_Money11
EZ_Money11 Feb. 28 at 12:20 PM
$ACCD Maybe wait to see if it fills the gap around $3.70…..
0 · Reply
ribockski
ribockski Feb. 24 at 3:37 AM
1. Accolade Inc. ($ACCD): A healthcare company, Accolade has experienced a significant 97% increase in its stock price over the past 30 days, indicating strong growth potential. 2. Akero Therapeutics Inc. ($AKRO): A biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH), Akero has seen its stock price rise by 96.2% over the past month. 3. OppFi Inc. ($OPFI): A financial technology company, OppFi has demonstrated a 93.1% increase in its stock price over the past 30 days, suggesting robust growth prospects.
0 · Reply
Quantum_Capital_LLC
Quantum_Capital_LLC Feb. 23 at 10:57 AM
$MPLN $APPS $CRNC $TUYA what I am currently buying/accumulating; they have strong momentum & technical indicators are favorable for either near term bullish move or long term positive move. $ACCD on watch.
0 · Reply
ajmrtxl
ajmrtxl Feb. 18 at 4:15 PM
$ACCD latest data from Squeezefinder
0 · Reply
jasonthegreat1
jasonthegreat1 Jan. 21 at 5:58 PM
$ACCD $5 puts exp March 21st are virtually free. Good hedge just in case things don't work out. Call it insurance.
0 · Reply
djotc
djotc Jan. 10 at 9:07 PM
$ACCD this thing should have nose dived by
1 · Reply
d_risk
d_risk Jan. 10 at 4:01 PM
$ACCD - Accolade Inc. Common Stock - 10Q - Updated Risk Factors New risks from the pending Transcarent merger include business disruptions, employee uncertainty, legal challenges, deal restrictions, and significant fallout if it fails. Completion remains uncertain. #Risk https://d-risk.ai/ACCD/10-Q/2025-01-10
0 · Reply
kuhii
kuhii Jan. 10 at 2:39 PM
$ACCD did they even report
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Jan. 10 at 1:43 AM
Top watch for a crazy move ticker -🚨 MCVT 🚨 Check it out, no dilution. Tiny float, cash flow positive. And now a massive short squeeze setting up. $SANA $ACCD $CURR $SILO
0 · Reply
topstockalerts
topstockalerts Jan. 9 at 7:52 PM
$ACCD can she keep going up?
0 · Reply
anachartanalyst
anachartanalyst Jan. 9 at 7:01 PM
$ACCD https://anachart.com/wp-content/uploads/ana_temp/1736449293_soc-img.jpg
0 · Reply